New combo therapy aims to wipe out lymphoma without prior treatment
NCT ID NCT07480863
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (orelabrutinib, zuberitamab, and chemotherapy) in 65 adults with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the treatment can make all signs of cancer disappear for at least 24 months. Participants must be 18 or older, in good general health, and have measurable tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, beijing,
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a maintenance drug keep lymphoma at bay? new trial aims to find out.
- New drug takes aim at Hard-to-Treat blood cancers
- CAR-T therapy Follow-Up study shows no new safety surprises
- New Risk-Adapted drug combo aims to outsmart lymphoma
- New combo therapy aims to shrink lymphoma tumors in untreated patients
- Experimental drug voruciclib tested in desperate blood cancer patients